Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
2.98M
-
Shares change
-
+1.3M
-
Total reported value, excl. options
-
$6.64M
-
Value change
-
+$1.67M
-
Put/Call ratio
-
0.16
-
Number of buys
-
16
-
Number of sells
-
-10
-
Price
-
$2.23
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q2 2022
37 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.98M shares
of 107M outstanding shares and own 2.79% of the company stock.
Largest 10 shareholders include Empery Asset Management, LP (928K shares), VANGUARD GROUP INC (830K shares), BlackRock Inc. (258K shares), Alyeska Investment Group, L.P. (254K shares), GEODE CAPITAL MANAGEMENT, LLC (145K shares), Equitable Holdings, Inc. (110K shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (100K shares), MORGAN STANLEY (91.5K shares), STATE STREET CORP (51.2K shares), and CITADEL ADVISORS LLC (37.6K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.